Indication
Metastatic Esophageal Cancer
3 clinical trials
5 products
3 drugs
Clinical trial
A Randomised Phase II Study of Zimberelimab Anti-PD1 immunOtherapy +/- Domvanalimab Anti-TIGIT Immunotherapy in Resectable Mismatch Repair Deficient Gastric and Gastro-oesophageal Junctional AdenoCarcinomaStatus: Not yet recruiting, Estimated PCD: 2026-09-01
Product
ZimberelimabProduct
Zimberelimab + DomvanalimabClinical trial
A Phase II Study of agenT-797 (Invariant Natural Killer T Cells), Botensilimab, a Novel Fc-enhanced CTLA-4 Inhibitor, Plus Balstilimab (Anti-PD-1) With Ramucirumab and Paclitaxel for Patients With Previously Treated, Advanced Esophageal, Gastric, or Gastro-esophageal Junction AdenocarcinomaStatus: Recruiting, Estimated PCD: 2027-08-01
Product
AgenT-797Drug
BotensilimabProduct
BalstilimabProduct
RamucirumabDrug
TiragolumabClinical trial
A Multicenter Phase II Non-randomised Trial Assessing the Efficacy of DKN-01 Plus Atezolizumab in Patients With Advanced Mismatch Repair Proficient Oesophagogastric CancerStatus: Recruiting, Estimated PCD: 2024-05-30
Drug
Atezolizumab